Clozapine Increases Response After One Failed Antipsychotic in Early Psychosis

Approximately one-quarter of patients experiencing first-episode psychosis will develop treatment-resistant schizophrenia during the early stages of their illness [1]. Current clinical guidelines generally recommend sequential trials of standard antipsychotics, reserving clozapine for patients who have failed at least two adequate pharmacological interventions [2]. However, response rates drop precipitously with each subsequent medication change, falling from roughly 53% in the first stage to just 26% in the second [2]. This diminishing return has prompted researchers to question whether identifying treatment resistance earlier and expediting clozapine therapy could prevent prolonged periods of uncontrolled symptoms [3]. A recent randomized clinical trial now provides direct evidence on the efficacy of moving clozapine up the treatment algorithm to immediately follow a single failed antipsychotic trial.